Birzeit Pharmaceutical Co (XPAE:BPC) ROCE %: 7.22% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAE:BPC Birzeit Pharmaceutical Co XPAE:BPC
91 GF Score
Price $3.67
GF Value $4.59
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Birzeit Pharmaceutical Co ROCE %?

Birzeit Pharmaceutical Co XPAE:BPC -0.27% 91 ROCE % is 7.22% as of Mar. 2026. GuruFocus rates XPAE:BPC with a GF Score™ of 91/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Birzeit Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.22%.

Birzeit Pharmaceutical Co  (XPAE:BPC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Birzeit Pharmaceutical Co ROCE % Related Terms

Birzeit Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Birzeit Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Birzeit Pharmaceutical Co ROCE % Chart

Birzeit Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.82 8.30 6.10 5.22 10.79

Birzeit Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 23.13 7.73 8.00 7.22
XPAE:BPC
91GF Score
Birzeit Pharmaceutical Co XPAE:BPC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Birzeit Pharmaceutical Co ROCE % Calculation

Birzeit Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=13.132/( ( (128.821 - 12.845) + (140.206 - 12.844) )/ 2 )
=13.132/( (115.976+127.362)/ 2 )
=13.132/121.669
=10.79 %

Birzeit Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=9.2/( ( (140.206 - 12.844) + (146.137 - 18.717) )/ 2 )
=9.2/( ( 127.362 + 127.42 )/ 2 )
=9.2/127.391
=7.22 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.22% mean?
Birzeit Pharmaceutical Co (XPAE:BPC) has a ROCE % of 7.22% as of Mar. 2026.
Is Birzeit Pharmaceutical Co's ROCE % too high?
Birzeit Pharmaceutical Co's current ROCE % is 7.22%. The Drug Manufacturers industry median ROCE % is 7.04. Birzeit Pharmaceutical Co's value of 7.22% is 2.6% above this industry median. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's ROCE % compare to ZTS and UTHR?
Birzeit Pharmaceutical Co's ROCE % of 7.22% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Birzeit Pharmaceutical Co's value of 7.22% is 2.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current ROCE % of 7.22% is 2.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current ROCE % is 7.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current ROCE % is 7.22% and 2.6% above the Drug Manufacturers industry median of 7.04. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current ROCE % is 7.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?

Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued. The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59. GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for XPAE:BPC:

  • ROCE %: 7.22%
  • GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
  • GF Score™: 91/100 with 3 warning signs
  • Industry Position: 2.6% above the Drug Manufacturers median

No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Birzeit Pharmaceutical Co Business Description

Address 20 Shatella Street, Betunia Industrial Area, Ramallah, PSE
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score

Get the complete analysis for XPAE:BPC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.67
Price
$4.59
GF Value